Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 16, Issue 4 , Pages 483-497 , August 2002

Molecular aspects of ovarian cancer

References 

    REFERENCES
  1. Cramer DW, Hutchinson GB, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. Journal of the National Cancer Institute. 1983;71:717–721
  2. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk. Collaborative analysis of twelve US case-control studies. II. Invasive epithelial ovarian cancers in white women. American Journal of Epidemiology. 1992;136:1184–1203
  3. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. Journal of the National Cancer Institute. 1997;89:932–938
  4. Rodriguez GC, Walmer DK, Cline M. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?. Journal of the Society for Gynecologic Investigation. 1998;5:271–276
  5. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. Journal of the National Cancer Institute. 1998;90:1774–1786
  6. Silva EG, Tornos C, Fritsche HA. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Modern Pathology. 1997;10:879–893
  7. Helzlsouer KJ, Alberg AJ, Gordon GB. Serum gonadotropins and steroid hormones and the development of ovarian cancer. Journal of the American Medical Association. 1995;274:1926–1930
  8. Schildkraut JM, Schwingl PJ, Bastos E. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstetrics and Gynecology. 1996;88:554–559
  9. Gallion HH, Powell DE, Smith LW. Chromosome abnormalities in human epithelial ovarian malignancies. Gynecologic Oncology. 1990;38:473–477
  10. Iwabuchi H, Sakamoto M, Sakunaga H. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Research. 1995;55:6172–6180
  11. Dodson MK, Hartman LC, Cliby WA. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Research. 1993;53:4456–4460
  12. Welsh KJ, Zarrinkar PP, Sapinoso LM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the USA. 2001;98:1176–1181
  13. Shridhar V, Lee J, Pandita A. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Research. 2001;61:5895–5904
  14. Kerns BJ, Jordan PA, Faerman LL. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. American Journal of Clinical Pathology. 1994;101:192–197
  15. Hartmann LC, Sebo TJ, Kamel NA. Proliferating cell nuclear antigen in epithelial ovarian cancer: relation to results at second-look laparotomy and survival. Gynecologic Oncology. 1992;47:191–195
  16. Garzetti GG, Ciavattini A, Goteri G. Ki67 antigen immunostaining [MIB 1 monoclonal antibody] in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecologic Oncology. 1995;56:169–174
  17. Berchuck A, Olt GJ, Everitt L. The role of peptide growth factors in epithelial ovarian cancer. Obstetrics and Gynecology. 1990;75:225–262
  18. Mills GB, May C, Hill M. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. Journal for Clinical Investigation. 1990;86:851–855
  19. Rodriguez GC, Berchuck A, Whitaker RS. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. American Journal of Obstetrics and Gynecology. 1991;164:745–750
  20. Berchuck A, Rodriguez GC, Olt GJ. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β. American Journal of Obstetrics and Gynecology. 1992;166:676–684
  21. Hurteau J, Rodriguez GC, Whitaker RS. Effect of transforming growth factor-β on on proliferation of human ovarian cancer cells obtained from ascites. Cancer. 1994;74:93–99
  22. Herod JJ, Eliopoulos AG, Warwick J. The prognostic significance of Bcl 2 and p53 expression in ovarian carcinoma. Cancer Research. 1996;56:2178–2184
  23. Henriksen R, Wilander E, Oberg K. Expression and prognostic significance of Bcl-2 in ovarian tumours. British Journal of Cancer. 1995;72:1324–1329
  24. Liu JR, Fletcher B, Page C. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecologic Oncology. 1998;70:398–403
  25. Tai YT, Lee S, Niloff E. BAX protein expression and clinical outcome in epithelial ovarian cancer. Journal of Clinical Oncology. 1998;16:2583–2590
  26. Shay JW. Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. Cancer Journal From Scientific American. 1998;4:S26–S34
  27. Duggan BD, Wan M, Yu MC. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. Journal of the National Cancer Institute. 1998;90:238–242
  28. Wan M, Li WZ, Duggan BD. Telomerase activity in benign and malignant epithelial ovarian tumors. Journal of the National Cancer Institute. 1997;89:437–441
  29. Berchuck A, Carney M, Lancaster JM. Familial breast–ovarian cancer syndromes: BRCA1 and BRCA2. Clinical Obstetrics and Gynecology. 1998;41:157–166
  30. Lynch HT, Casey MJ, Lynch J. Genetics and ovarian carcinoma. Seminars in Oncology. 1998;25:265–280
  31. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology. 1998;12:399–406
  32. Berchuck A, Heron K, Carney ME. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clinical Cancer Research. 1998;4:2433–2437
  33. Takahashi H, Behbakht K, McGovern PE. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Research. 1995;55:2998–3002
  34. Stratton JF, Gayther SA, Russell P. Contribution of BRCA1 mutations to ovarian cancer. New England Journal of Medicine. 1997;336:1125–1130
  35. Rubin SC, Benjamin I, Behbakht K. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. New England Journal of Medicine. 1996;335:1413–1416
  36. Modan B. BRCA1 mutations and survival in women with ovarian cancer. New England Journal of Medicine. 1997;336:1255–1257
  37. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. Journal of Clinical Oncology. 1998;16:397–404
  38. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case–control studies of ovarian cancer. American Journal of Human Genetics. 1997;60:496–504
  39. Narod SA, Risch H, Moslehi R. Oral contraceptives and the risk of hereditary ovarian cancer. New England Journal of Medicine. 1998;339:424–428
  40. Gayther SA, Warren W, Mazoyer S. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for genotype-phenotype correlation. Nature Genetics. 1995;11:428–433
  41. Shattuck-Eidens D, Oliphant A, McClure M. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. Journal of the American Medical Association. 1997;278:1242–1250
  42. Phelan CM, Lancaster JM, Cumbs C. Mutation analysis of the BRCA2 gene in 49 site-specfic breast cancer families. Nature Genetics. 1996;13:120–122
  43. Frank TS, Manley SA, Olopade OI. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology. 1998;17:2417–2425
  44. Gayther SA, Mangion J, Russell P. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genetics. 1997;15:103–105
  45. Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. American Journal of Human Genetics. 1998;62:676–689
  46. Narod S, Goldgar D, Cannon-Albright L. Risk modifiers in carriers of BRCA1 mutations. International Journal of Cancer. 1995;64:394–398
  47. Muto MG, Cramer DW, Tangir J. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Research. 1996;56:1250–1252
  48. Levy-Lahad E, Catane R, Eisenberg S. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast–ovarian cancer families. American Journal of Human Genetics. 1997;60:1059–1067
  49. Watson P, Butzow R, Lynch HT. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic Oncology. 2001;82:223–228
  50. Lynch HT, Lemon SJ, Karr B. Etiology, natural history, management and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): genetic counseling implications. Cancer Epidemiology, Biomarkers and Prevention. 1997;6:987–991
  51. Lynch HT, Smyrk T, Lynch J. An update of HNPCC (Lynch syndrome). Cancer Genetics and Cytogenetics. 1997;93:84–99
  52. Lynch HT, Lynch J. Genetic counseling for hereditary cancer. Oncology. 1996;10:27–32
  53. Aziz S, Kuperstein G, Rosen B. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecologic Oncology. 2001;80:341–345
  54. Modan B, Hartge P, Hirsh-Yechezkel G. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2001;345:235–240
  55. Jacobs IJ, Kohler MF, Wiseman RW. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. Journal of the National Cancer Institute. 1992;84:1793–1798
  56. Slamon DJ, Godolphin W, Jones LA. Studies of HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  57. Berchuck A, Kamel A, Whitaker R. Overexpression of HER-2/ neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Research. 1990;50:4087–4091
  58. Rubin SC, Finstad CL, Wong GY. Prognostic significance of HER-2/ neu expression in advanced ovarian cancer. American Journal of Obstetrics and Gynecology. 1993;168:162–169
  59. Rodriguez GC, Boente MP, Berchuck A. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. American Journal of Obstetrics and Gynecology. 1993;168:228–232
  60. Pietras RJ, Pegram MD, Finn RS. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998;17:2235–2249
  61. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 2001;344:783–792
  62. Enomoto T, Inoue M, Perantoni AO. K- ras activation in neoplasms of the human female reproductive tract. Cancer Research. 1990;50:6139–6145
  63. Feig LA, Bast RC, Knapp RC, Cooper GM. Somatic activation of ras K gene in a human ovarian carcinoma. Science. 1984;223:698–701
  64. Teneriello MG, Ebina M, Linnoila RI. p53 and ki- ras gene mutations in epithelial ovarian neoplasms. Cancer Research. 1993;53:3103–3108
  65. Mok S CH, Bell DA, Knapp RC. Mutation of K- ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Research. 1993;53:1489–1492
  66. Shayesteh L, Lu Y, Kuo WL. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics. 1999;21:99–102
  67. Cheng JQ, Godwin AK, Bellacosa A. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proceedings of the National Academy of Sciences of the USA. 1992;89:9267–9271
  68. Tashiro H, Niyazaki K, Okamura H. c- myc over-expression in human primary ovarian tumors: Its relevance to tumor progression. International Journal of Cancer. 1992;50:828–883
  69. Liggett W HJ, Sidransky D. Role of the p16 tumor suppressor gene in cancer. Journal of Clinical Oncology. 1998;16:1197–1206
  70. Casey G, Lopez ME, Ramos JC. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996;13:1971–1981
  71. Hartmann L, Podratz K, Keeney G. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. Journal of Clinical Oncology. 1994;12:64–69
  72. Berchuck A, Kohler MF, Marks JR. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. American Journal of Obstetrics and Gynecology. 1994;170:246–252
  73. Berchuck A, Kohler MF, Hopkins MP. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecologic Oncology. 1994;52:232–236
  74. Marks JR, Davidoff AM, Kerns B. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Research. 1991;51:2979–2984
  75. Reles A, Wen WH, Schmider A. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clinical Cancer Research. 2001;7:2984–2997
  76. Obata K, Morland SJ, Watson RH. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Research. 1998;58:2095–2097
  77. Havrilesky L, Alvarez AA, Whitaker RS. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecologic Oncology. 2001;83:491–500

PII: S1521-6934(02)90298-1

doi: 10.1053/beog.2002.0298

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 16, Issue 4 , Pages 483-497 , August 2002

Article Tools